Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;64(7):641-4.
doi: 10.1590/S1807-59322009000700006.

Prostasin, a potential tumor marker in ovarian cancer--a pilot study

Fernanda Pires Costa  1 , Eraldo Luis Batista Jr, Alice Zelmanowicz, Christer Svedman, Gabriela Devenz, Silvana Alves, Andrea Simões Martins da Silva, Bernardo Garicochea
Affiliations

Prostasin, a potential tumor marker in ovarian cancer--a pilot study

Fernanda Pires Costa et al. Clinics (Sao Paulo). 2009.

Abstract

Introduction: Ovarian cancer is generally diagnosed at advanced stages of the disease; therefore, poor prognoses are typical. The development of tumor markers is thus of utmost importance. Prostasin is a protease that in normal tissues is highly expressed only in the prostate gland and seminal fluid. A previous study showed that prostasin is highly overexpressed in ovarian cancer cell lines. This study sought to evaluate the expression of prostasin in ovarian cancer.

Methods: Fresh tumor samples of ovarian epithelial cancer (n: 12) were analyzed for expression of prostasin mRNA (messenger ribonucleic acid) by conventional and real time quantitative PCR (polymerase chain reaction). As a standard control, a normal prostate sample was analyzed.

Results: Using conventional PCR, prostasin was detected in all but one sample. Using quantitative PCR, prostasin was over-expressed in all but one of the samples as compared to the control (prostate).

Conclusions: These findings indicate that prostasin is overexpressed in many epithelial ovarian cancers. Further studies of prostasin as a potential biomarker for this disease are warranted.

Keywords: Biomarker; Detection; Diagnostic; PRSS8; Screening.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30. - PubMed
    1. Pascalicchio JC, Fristachi CE, Castanho PL, Kue CM, Piato S, Baracat FF. Epidemiologia do câncer de ovário no Brasil. RSBC. 2000;11:46–53.
    1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al. SEER Cancer Statistics Review, 1975–2005. National Cancer Institute; Bethesda, MD: 2008.
    1. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535–8. - PMC - PubMed
    1. Bast RC, Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Marker. 1998;13:179–87. - PubMed

Publication types